Polo-like Kinase | Cell Cycle| CSNpharm

You are here: Home /
Cell Cycle /
PLK

PLK

PLK

Items: 1–10 of

Show:

50

20

50

100

Cat. No.	Product Name	CAS No.	Information
CSN23160	TC-S 7005	1082739-92-1	TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively[1].
CSN15714	TAK-960	1137868-52-0	TAK-960 is an investigational orally bioavailable potent and selective PLK1 inhibitor IC5015 nM that has shown activity in several tumor cell lines including those that express multidrug-resistant protein 1 MDR1
CSN17496	TAK-960 HCl	2108449-45-0	TAK-960 HCl is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).
CSN16924	SBE13 HCl	1052532-15-6	SBE13 HCl is a potent and selective PLK1 inhibitor with IC50 of 02 nM while 875 nM and 66 M for PLK3 and PLK2 SBE 13 could also induce cell cycle arrest reduce cell proliferation with EC50 of 5-60 M and induce apoptosis in a broad range of human cancer cell lines
CSN16422	Ro 3280	1062243-51-9	RO3280 is a potent highly selective inhibitor of Polo-like kinase 1 PLK1 with IC50 of 3 nM
CSN18787	Rigosertib Sodium	592542-60-4	Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM
CSN15803	Rigosertib Sodium (Random Configuration)	1225497-78-8	Rigosertib Sodium (Random Configuration) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3.
CSN18349	Rigosertib	592542-59-1	Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM and shows 30-fold greater selectivity against PLK2 and no activity to PLK3
CSN18210	Poloxin	321688-88-4	Poloxin is a non-ATP competitive Polo-like Kinase 1 PLK1 inhibitor that targets the polo-box domain
CSN18009	Poloxime	17302-61-3	Poloxime is an analogue of thymoquinone which bind to the phosphoserinephosphothreonine recognition site of the polo-box domain of polo-like kinase 1
CSN16295	NMS-1286937	1034616-18-6	NMS-1286937 is an orally bioavailable small-molecule Polo-like kinase 1 PLK1 inhibitor IC502 nM with potential antineoplastic activity and no inhibition on PLK2 and PLK3
CSN16314	MLN0905	1228960-69-7	MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM
CSN18151	LFM-A13	244240-24-2	LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 172 M and also inhibits PLK3 with IC50 of 72 M
CSN16519	HMN-214	173529-46-9	HMN-214 is a potent PLK1 inhibitor an average IC50 of 012 M and a prodrug of HMN-176 which alters the cellular spatial orientation of Plk1
CSN19103	HMN-176	173529-10-7	HMN-176 is the active derivative of HMN-214 which can alter the cellular spatial orientation of Plk1
CSN12710	GW843682X	660868-91-7	GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 22 nM PLK1 and 91 nM PLK3 and displays 100-fold selectivity over 30 other kinases tested including cdk1 and cdk2
CSN12716	GSK461364	929095-18-1	GSK461364 is a potent small molecule Polo-like kinase 1 PLK1 inhibitor with a Ki of 22 nM
CSN22785	Cyclapolin 9	40533-25-3	Cyclapolin 9 is a selective, ATP-competitive polo-like kinase 1 (PLK1) inhibitor with IC50 of 500 nM.
CSN18037	Centrinone-B	1798871-31-4	Centrinone-B is a high affinity and selective PLK4 inhibitor Ki 059 nM
CSN17208	Centrinone	1798871-30-3	Centrinone is a selective and reversible inhibitor of polo-like kinase 4 Plk4 a serine-threonine protein kinase that initiates centriolecentrosome assembly
CSN12712	Volasertib	755038-65-4	BI6727 is an ATP-competitive kinase inhibitor from the dihydropteridinone class of compounds.
CSN12461	BI-2536	755038-02-9	BI-2536 is a potent Plk1 inhibitor with IC50 of 083 nM BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3 and also is a BRD4 inhibitor IC50 25 nM

<< PREV 1 NEXT >>

PLK Items: 1–10 of Show: 50 20 50 100

50

PLK

Items: 1–10 of

Show:

50

20

50

100